• Consensus Rating: Moderate Buy
  • Consensus Price Target: $16.50
  • Forecasted Upside: 3.51%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$15.94
▲ +0.11 (0.69%)

This chart shows the closing price for CDNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CareDx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDNA

Analyst Price Target is $16.50
▲ +3.51% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for CareDx in the last 3 months. The average price target is $16.50, with a high forecast of $22.00 and a low forecast of $12.00. The average price target represents a 3.51% upside from the last price of $15.94.

This chart shows the closing price for CDNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 polled investment analysts is to moderate buy stock in CareDx. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2024Craig HallumBoost TargetBuy ➝ Buy$15.00 ➝ $22.00Low
5/15/2024HC WainwrightReiterated RatingNeutralLow
5/13/2024Raymond JamesDowngradeOutperform ➝ Market PerformLow
5/13/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$10.00 ➝ $14.00Low
5/13/2024StephensBoost TargetOverweight ➝ Overweight$15.00 ➝ $18.00Low
5/9/2024Craig HallumReiterated RatingBuy ➝ Buy$15.00Low
5/1/2024Craig HallumUpgradeHold ➝ Buy$12.00 ➝ $15.00Low
4/17/2024StephensReiterated RatingOverweight ➝ Overweight$15.00Low
11/9/2023StephensUpgradeEqual Weight ➝ Overweight$10.00Low
9/26/2023StephensReiterated RatingEqual Weight ➝ Equal Weight$10.00Low
8/15/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$12.00Low
8/9/2023HC WainwrightReiterated RatingNeutralLow
5/11/2023BTIG ResearchDowngradeBuy ➝ NeutralLow
3/7/2023The Goldman Sachs GroupLower TargetBuy$25.00 ➝ $13.00Low
3/7/2023StephensDowngradeOverweight ➝ Equal Weight$19.00 ➝ $9.00Low
3/3/2023Craig HallumDowngradeBuy ➝ Hold$26.00 ➝ $9.00Low
3/3/2023Raymond JamesDowngradeStrong-Buy ➝ Market Perform$24.00Low
2/28/2023StephensReiterated RatingOverweight$19.00Low
2/28/2023BTIG ResearchLower TargetBuy$28.00 ➝ $25.00Low
2/28/2023Craig HallumLower TargetBuy$32.00 ➝ $26.00Low
2/28/2023The Goldman Sachs GroupLower TargetBuy$29.00 ➝ $25.00Low
2/16/2023StephensReiterated RatingOverweight$19.00Low
2/6/2023The Goldman Sachs GroupLower TargetBuy$40.00 ➝ $29.00Low
1/31/2023Raymond JamesLower TargetStrong-Buy$26.00 ➝ $24.00Low
11/7/2022Raymond JamesLower TargetStrong-Buy$35.00 ➝ $26.00Low
11/7/2022BTIG ResearchLower TargetBuy$37.00 ➝ $28.00Low
11/4/2022The Goldman Sachs GroupLower TargetBuy$45.00 ➝ $40.00Low
8/15/2022BTIG ResearchLower Target$37.00Low
4/25/2022StephensInitiated CoverageOverweight$50.00High
2/28/2022BTIG ResearchLower Target$100.00 ➝ $65.00High
2/25/2022Craig HallumLower Target$106.00 ➝ $87.00Low
2/25/2022Raymond JamesLower TargetStrong-Buy$90.00 ➝ $52.00Medium
10/29/2021BTIG ResearchReiterated RatingBuy$99.00Low
10/29/2021Raymond JamesLower TargetStrong-Buy$108.00 ➝ $90.00High
7/30/2021Piper SandlerBoost TargetOverweight$100.00 ➝ $110.00High
7/20/2021BTIG ResearchInitiated CoverageBuy$115.00Low
6/28/2021Raymond JamesBoost TargetStrong-Buy$90.00 ➝ $108.00Medium
6/3/2021The Goldman Sachs GroupInitiated CoverageBuy$95.00Low
5/6/2021Raymond JamesLower TargetStrong-Buy$98.00 ➝ $90.00High
5/6/2021Piper SandlerBoost TargetOverweight$93.00 ➝ $100.00High
3/3/2021Raymond JamesLower TargetStrong-Buy$101.00 ➝ $98.00High
2/26/2021HC WainwrightDowngradeBuy ➝ NeutralLow
2/25/2021Raymond JamesReiterated RatingStrong-Buy$98.00Low
1/12/2021Piper SandlerBoost TargetOverweight$62.00 ➝ $93.00Medium
1/4/2021Craig HallumBoost TargetBuy$66.00 ➝ $94.00N/A
12/17/2020BTIG ResearchBoost TargetBuy$55.00 ➝ $80.00High
12/10/2020Raymond JamesBoost TargetStrong-Buy$62.00 ➝ $75.00High
10/30/2020Raymond JamesBoost TargetStrong-Buy$42.00 ➝ $62.00High
10/30/2020HC WainwrightBoost TargetBuy$47.00 ➝ $55.00High
10/8/2020BTIG ResearchBoost TargetBuy$45.00 ➝ $55.00High
10/8/2020Craig HallumBoost TargetBuy$46.00 ➝ $66.00High
10/8/2020HC WainwrightBoost TargetBuy$45.00 ➝ $47.00High
10/8/2020Piper SandlerBoost TargetOverweight$54.00 ➝ $62.00High
10/2/2020HC WainwrightBoost TargetBuy$40.00 ➝ $45.00Low
8/10/2020Jefferies Financial GroupReiterated RatingBuy$35.00High
8/6/2020BTIG ResearchBoost TargetBuy$40.00 ➝ $45.00Medium
8/5/2020Raymond JamesBoost TargetStrong-Buy$40.00 ➝ $42.00High
8/5/2020HC WainwrightBoost TargetBuy$37.00 ➝ $40.00High
6/29/2020Piper SandlerReiterated RatingBuy$54.00High
6/26/2020BTIG ResearchInitiated CoverageBuy$40.00High
6/19/2020Raymond JamesReiterated RatingBuy$40.00High
6/19/2020HC WainwrightReiterated RatingBuy$40.00 ➝ $37.00High
5/18/2020HC WainwrightReiterated RatingBuy$40.00High
5/1/2020HC WainwrightLower TargetBuy$43.00 ➝ $40.00High
5/1/2020Piper SandlerLower TargetOverweight$59.00 ➝ $54.00High
4/24/2020HC WainwrightReiterated RatingBuy$43.00High
4/9/2020Craig HallumLower TargetBuy$48.00 ➝ $42.00Medium
3/23/2020HC WainwrightReiterated RatingBuyHigh
1/27/2020Piper SandlerReiterated RatingBuy$63.00High
1/21/2020HC WainwrightReiterated RatingBuy$43.00High
11/1/2019Piper Sandler CompaniesSet TargetBuy$63.00N/A
10/1/2019Craig HallumInitiated CoverageBuy$48.00Low
8/23/2019HC WainwrightSet TargetBuy$43.00Low
8/22/2019Piper Sandler CompaniesSet TargetBuy$63.00Low
8/2/2019HC WainwrightReiterated RatingBuyLow
8/2/2019Raymond JamesBoost TargetStrong-Buy$46.00 ➝ $48.00High
8/2/2019Piper Sandler CompaniesBoost TargetOverweight$50.00 ➝ $63.00Medium
7/11/2019Craig HallumSet TargetBuy ➝ Positive$40.00 ➝ $48.00Low
(Data available from 5/27/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2023
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/29/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/29/2023
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/28/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/27/2024
  • 6 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/28/2024
  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2024
  • 13 very positive mentions
  • 29 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/27/2024

Current Sentiment

  • 13 very positive mentions
  • 29 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
CareDx logo
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $15.94
Low: $15.53
High: $17.03

50 Day Range

MA: $10.62
Low: $7.56
High: $15.94

52 Week Range

Now: $15.94
Low: $4.80
High: $17.03

Volume

587,600 shs

Average Volume

920,260 shs

Market Capitalization

$830.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Frequently Asked Questions

What sell-side analysts currently cover shares of CareDx?

The following Wall Street analysts have issued stock ratings on CareDx in the last year: Craig Hallum, HC Wainwright, Raymond James, Stephens, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for CDNA.

What is the current price target for CareDx?

4 Wall Street analysts have set twelve-month price targets for CareDx in the last year. Their average twelve-month price target is $16.50, suggesting a possible upside of 3.5%. Craig Hallum has the highest price target set, predicting CDNA will reach $22.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $12.00 for CareDx in the next year.
View the latest price targets for CDNA.

What is the current consensus analyst rating for CareDx?

CareDx currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CDNA.

What other companies compete with CareDx?

How do I contact CareDx's investor relations team?

CareDx's physical mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (415) 287-2300 and its investor relations email address is [email protected]. The official website for CareDx is www.caredxinc.com. Learn More about contacing CareDx investor relations.